In recent trading, shares of Tenet Healthcare Corp. (Symbol: THC) have surpassed the average analyst 12-month target price of $202.50, currently trading at $203.04 per share. When a stock reaches an analyst’s target, they typically have two options: either downgrade the stock due to valuation concerns or adjust their target price upward. The analyst’s response may also hinge on the fundamental business developments that have driven the stock price higher. If the outlook for the company is positive, it could be time to raise that target price.
Within the Zacks coverage universe, there are 20 different analyst targets contributing to the average for Tenet Healthcare Corp. However, this average is merely a mathematical calculation. Some analysts have set lower targets, with one predicting a price of $167.00, while another has set a target as high as $238.00. The standard deviation among these targets is $19.632, indicating a range of opinions.
The primary reason for examining the average THC price target is to leverage a “wisdom of crowds” approach. This method aggregates the insights of multiple analysts rather than relying on a single expert’s opinion. With THC now trading above the average target price of $202.50 per share, investors are presented with a valuable opportunity to reassess the company. They must decide whether $202.50 is merely a stepping stone toward an even higher target or if the valuation has become too stretched, prompting a consideration of taking some profits. Below is a table showcasing the current perspectives of analysts covering Tenet Healthcare Corp:
| Recent THC Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Month Ago | 3 Month Ago |
| Strong buy ratings: | 16 | 16 | 16 | 16 |
| Buy ratings: | 3 | 3 | 3 | 3 |
| Hold ratings: | 3 | 3 | 3 | 2 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.39 | 1.39 | 1.39 | 1.31 |
The average rating in the table above ranges from 1 to 5, where 1 indicates a Strong Buy and 5 indicates a Strong Sell. This article utilized data provided by Zacks Investment Research via Quandl.com. For the latest Zacks research report on THC, click here.
10 ETFs With Most Upside To Analyst Targets »
Also see:
• Stocks with Recent Secondaries That Hedge Funds Are Selling
• Funds Holding JBIO
• Diagnostics mergers and acquisitions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
